指南与共识间质性肺疾病

中国专家共识:肺活检在间质性肺疾病中的临床应用

[Chinese expert consensus on the clinical application of lung biopsy in interstitial lung disease].
指南 / 共识 · Zhonghua Jie He He Hu Xi Za Zhi · 2026-01-01

本共识由中国医师协会呼吸医师分会和中国胸科协会ILD学组牵头,联合多学科专家制定,采用系统文献综述、证据分级和Delphi法匿名投票,形成15条推荐。共识以多学科讨论为核心,系统阐述肺活检必要性评估、适应证分层、技术选择、围术期管理、病理报告规范及特殊临床情境决策。

要点

  • 疑似ILD患者肺活检前必须进行多学科讨论,评估诊断确定性、活检临床效用并共享决策。
  • HRCT呈明确UIP型且已排除继发病因者强烈不推荐肺活检;不确定型或非UIP型且临床证据不足者强烈推荐活检。
  • TBLB推荐用于疑似肉芽肿性疾病和特定肺泡填充型,不推荐用于以纤维化为主的ILD。

核心结论

  • 共识以多学科讨论为中心,系统规范肺活检在ILD诊疗全流程中的应用,旨在提供清晰、安全、实用的决策指导。

研究设计与样本

  • 由中国医师协会呼吸医师分会和中国胸科协会ILD学组牵头,联合呼吸、影像、病理、胸外科和风湿科专家制定。
  • 严格遵循循证医学原则,基于系统文献综述和证据分级,采用Delphi法匿名投票,形成15条推荐并标注证据水平和推荐强度。

主要发现

  • 共识系统阐述肺活检必要性评估、基于HRCT模式的适应证分层、四大活检技术的适用场景与选择路径、共享决策、围术期管理、AE-ILD管理、组织处理与病理报告标准化、活检后MDD整合诊断及特殊情境决策。
  • 推荐1:疑似ILD患者肺活检前必须进行MDD,评估诊断确定性、活检临床效用并促进共享决策(证据水平3,强推荐)。
  • 推荐3:HRCT明确UIP型且排除继发病因者强烈不推荐活检;可能UIP型且不能排除NSIP或纤维化HP者条件推荐活检;不确定型或非UIP型且临床证据不足者强烈推荐活检(证据水平4,条件推荐)。
  • 推荐6:急性呼吸衰竭、严重肺功能损害、近期心血管事件、血流动力学不稳定、显著肺动脉高压、严重凝血病或终末期全身衰弱者不推荐肺活检(证据水平1,强推荐)。
  • 推荐13:UIP组织学或影像模式、疾病活动期和DLCO降低是AE-ILD主要危险因素;不推荐对所有患者常规预防性使用糖皮质激素或抗纤维化治疗,推荐精细围术期管理预防急性加重(证据水平2,强推荐)。

关键数值与推荐

  • 推荐1:疑似ILD患者肺活检前必须进行MDD(证据水平3,强推荐)。
  • 推荐2:非侵入性评估后诊断仍不确定或需精确组织病理分型者推荐肺活检(证据水平4,强推荐)。
  • 推荐3:明确UIP型且排除继发病因者强烈不推荐活检;可能UIP型且不能排除NSIP或纤维化HP者条件推荐;不确定型或非UIP型且临床证据不足者强烈推荐(证据水平4,条件推荐)。
  • 推荐4:肺泡填充型在系统排除感染、肺泡出血和肺水肿后,经验性治疗无反应或需鉴别恶性肿瘤者推荐活检(证据水平2,强推荐)。
  • 推荐5:疑似罕见ILD(PAP、iEP、LAM、LIP)优先非侵入或微创诊断,非诊断时条件推荐活检;临床疑似AFOP或PLCH强烈推荐活检(证据水平2,条件推荐)。

临床怎么用

  • 临床应遵循MDD先行的原则,根据HRCT模式分层决定活检必要性,避免对明确UIP型且排除继发病因者进行不必要的活检。
  • 活检部位应选择HRCT上的活动性病变,标本需包含病变与正常肺组织交界区,避免大血管和严重肺大疱,推荐至少两个不同严重程度部位的多肺叶采样。
  • TBLB推荐用于疑似肉芽肿性疾病和特定肺泡填充型,非诊断时可升级至TBLC或SLB;不推荐用于以纤维化为主的ILD。
  • TBLC推荐在专家中心作为首选,尤其适用于不适合或不愿接受SLB者,应在全麻下标准化操作并预防性放置球囊控制出血。
  • SLB推荐用于TBLC非诊断且心肺生理储备允许手术者,首选VATS,需至少两个不同肺叶采样,优先上叶依赖段或下叶上段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interstitial lung disease (ILD) comprises a highly heterogeneous group of pulmonary disorders, whose diagnosis often requires the integration of clinical, radiologic, and pathologic evidence. Lung biopsy is a key method for obtaining a histopathologic diagnosis, but unified standards are lacking for determining indications, selecting biopsy techniques, managing patients perioperatively, and integrating pathologic and clinical information. To address these gaps, the Respiratory Physicians Branch of the Chinese Medical Doctor Association and the ILD Group of the Chinese Thoracic Society spearheaded this initiative, collaborating with national experts in respiratory medicine, radiology, pathology, thoracic surgery, and rheumatology to formulate this consensus. Developed in strict adherence to evidence-based medicine principles, this consensus is founded on systematic literature reviews and evidence grading, utilizing the Delphi method for anonymous voting. It culminates in 15 recommendations, each explicitly annotated with the level of evidence and strength of recommendation. This consensus systematically delineates the multidisciplinary discussion (MDD)-centered full-process management of lung biopsy. The main contents encompass: assessment of the necessity and feasibility of lung biopsy; indication stratification strategies based on HRCT patterns; applicability scenarios and selection pathways for the four major lung biopsy techniques; shared decision-making; perioperative comprehensive management; management strategies for acute exacerbation of ILD (AE-ILD); standardization of tissue processing and pathological reporting; the post-biopsy MDD process for integrated diagnosis; and biopsy decision-making in special clinical contexts, such as ILD complicated by lung cancer or connective tissue disease-associated ILD (CTD-ILD). This consensus aims to provide clinicians with clear, safe, and practical guidance on lung biopsy, promote standardized and precise decision-making, and improve patient outcomes.Summary of RecommendationsRecommendation 1: For patients with suspected ILD, a comprehensive multidisciplinary discussion (MDD) is mandatory prior to lung biopsy. This evaluation should establish the diagnostic certainty of the preliminary clinical assessment, evaluate the clinical utility of the biopsy, and facilitate shared decision-making (SDM) that incorporates patient preferences (Level of evidence: 3, Recommendation: strong).Recommendation 2: For ILD patients in whom the diagnosis remains uncertain following a comprehensive non-invasive evaluation, or when precise histopathologic subtyping is required, a lung biopsy is recommended to establish a definitive diagnosis and guide the therapeutic management (Level of evidence: 4, Recommendation: strong).Recommendation 3: For patients with an interstitial pattern, a lung biopsy is strongly discouraged if HRCT demonstrates a definite UIP pattern and secondary etiologies have been excluded. A conditional recommendation for a lung biopsy applies to patients with a probable UIP patterns in whom NSIP or fibrotic HP cannot be ruled out. A lung biopsy is strongly recommended to achieve a definitive diagnosis in patients with an indeterminate or non-UIP patterns and insufficient clinical evidence (Level of evidence: 4, Recommendation: conditional).Recommendation 4: For patients with an alveolar filling pattern, a lung biopsy is recommended to clarify the etiology once infection, alveolar hemorrhage, and pulmonary edema have been systematically excluded, and there is either a lack of response to empirical therapy or a clinical necessity to differentiate the lesion from malignancy (Level of evidence: 2, Recommendation: strong).Recommendation 5: For suspected rare ILDs, including PAP, iEP, LAM, and LIP, non-invasive or minimally invasive diagnostic modalities should be prioritized; a lung biopsy is conditionally recommended if these approaches are non-diagnositic. Conversely, a lung biopsy is strongly recommended for patients with clinically suspected AFOP or PLCH (Level of evidence: 2, Recommendation: conditional).Recommendation 6: Lung biopsy is not recommended for patients with acute respiratory failure, severe pulmonary functional impairment, recent cardiovascular events, hemodynamic instability, significant pulmonary hypertension, severe coagulopathy, or end-stage systemic debilitation (Level of evidence: 1, Recommendation: strong).Recommendation 7: Site selection for lung biopsy should target active lesions identified on HRCT (e.g., ground-glass opacities or fine reticulation). Specimens must include the interface between diseased and normal parenchyma to facilitate pattern assessment. High-risk areas, such as major vessels and severe bullae, must be strictly avoided. Multi-lobar sampling from at least two sites of varying severity is recommended to adequately capture disease heterogeneity (Level of evidence: 4, Recommendation: strong).Recommendation 8: A TBLB is recommended as the first-line diagnostic approach for suspected granulomatous diseases (e.g., sarcoidosis) and specific alveolar filling patterns. If a TBLB is non-diagnostic, escalation to TBLC or SLB is advised. A TBLB is not recommended for the evaluation of predominantly fibrotic ILDs (e.g., UIP or NSIP) (Level of evidence: 4, Recommendation: strong).Recommendation 9: TBLC is recommended as the preferred modality in expert centers, particularly for patients who are poor candidates for or are averse to SLB. The procedure should be standardized under general anesthesia with prophylactic balloon placement for hemorrhage control and integrated with imaging or navigational guidance to optimize diagnostic yield while minimizing procedural complications (Level of evidence: 2, Recommendation: strong).Recommendation 10: SLB is recommended for patients in whom TBLC yields a non-diagnostic result, provided their cardiopulmonary physiological reserve permits surgical intervention. Video-assisted thoracoscopic surgery (VATS) is the preferred approach, requiring sampling from at least two distinct lobes. Biopsies should prioritize the dependent segments of the upper lobes or the superior segments of the lower lobes; sampling from the lingula or the right middle lobe should only be considered if these sites harbor the most representative lesions and no superior alternatives exist (Level of evidence: 2, Recommendation: strong).Recommendation 11: PTNB is recommended for the diagnosis and differential diagnosis in ILD patients presenting with solitary nodules, masses, or focal consolidations, particularly to rule out malignancy. However, it is not recommended for the histopathological evaluation of diffuse fibrosing ILDs (Level of evidence: 2, Recommendation: strong).Recommendation 12: A shared decision-making model is recommended throughout the biopsy selection process. Clinicians should thoroughly counsel patients regarding the benefits, risks, and alternatives of the procedure, ultimately formulating a clinical plan that aligns medical evidence with patient values (Level of evidence: 4, Recommendation: strong).Recommendation 13: Histological or imaging patterns of usual interstitial pneumonia (UIP), active disease phase, and reduced diffusing capacity for carbon monoxide (DLCO) are the main risk factors for acute exacerbation of interstitial lung disease (AE-ILD). Routine prophylactic use of glucocorticoids or antifibrotic therapy is not recommended for all patients; instead, meticulous perioperative management is recommended to prevent acute exacerbations. Once AE occurs, the underlying cause should be promptly investigated, and high-dose glucocorticoids along with supportive therapy may be considered (Level of evidence: 2, Recommendation: strong).Recommendation 14: Histopathological reports must adhere to current international standardized nomenclature, prioritizing the description of the predominant histological patterns and their salient features, while specifically noting any findings indicative of a specific etiology. Diagnostic limitations secondary to suboptimal specimen quality must be explicitly stated. Pathologists are required to provide a systematic and standardized microscopic description of the tissue pathology, formulate a histopathological classification, and offer etiological insights whenever feasible (Level of evidence: 4, Recommendation: strong).Recommendation 15: Post-biopsy MDD is central to formulating an integrated diagnosis and should be conducted by the same cohort of clinicians, radiologists, and pathologists involved in the initial evaluation. A systematic correlation between the histopathology and the clinical andradiologic data is required; any discordances must be thoroughly analyzed to achieve a consensus integrated diagnosis and guide therapeutic planning. If an integrated diagnosis cannot be established, a subsequent MDD or referral to an expert center for a repeat biopsy is warranted (Level of evidence: 2, Recommendation: strong). 间质性肺疾病(ILD)是一组高度异质性的肺疾病,其诊断常需整合临床、影像及病理学证据。肺活检是获取组织病理学诊断的关键手段,但在指征把握、技术选择、围手术期管理及病理与临床信息整合等方面,尚缺乏统一规范。为此,中国医师协会呼吸医师分会和中华医学会呼吸病学分会间质性肺疾病学组牵头,联合国内呼吸病学、影像学、病理学、胸外科学及风湿病学等领域专家,共同制定本共识。共识制定严格遵循循证医学原则,基于系统性文献检索与证据评价,采用德尔菲法进行匿名投票,最终形成15条推荐意见,并明确标注证据等级与推荐强度。本共识系统阐述了以多学科讨论为核心的肺活检全流程管理,主要内容包括:肺活检必要性与可行性的评估、基于HRCT表现的适应证分层策略、四种主要肺活检技术的适用场景与选择路径、医患共同决策、AE-ILD的管理策略、组织标本处理与病理报告标准化以及活检后多学科讨论整合诊断流程。本共识旨在为临床医生提供清晰、安全、可操作的肺活检实践指导,推动ILD肺活检决策的规范化与精准化,改善患者预后。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Chinese expert consensus on the clinical application of lung biopsy in interstitial lung disease]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42811563. doi:10.3760/cma.j.cn112147-20260524-00302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。